Mechanical Stimulation in Preventing Bone Density Loss in Patients Undergoing Donor Stem Cell Transplant
Study Details
Study Description
Brief Summary
This pilot clinical trial studies mechanical stimulation in preventing bone density loss in patients undergoing donor stem cell transplant. Mechanical stimulation may limit, prevent, or reverse bone loss, increase muscle and cardiac performance, and improve overall health
Detailed Description
PRIMARY OBJECTIVES:
- To determine the feasibility of a mechanical stimulation regimen in hematopoietic cell transplant (HCT) patients.
SECONDARY OBJECTIVES:
- To evaluate the data collection tools to prepare for a larger phase II trial.
OUTLINE:
Patients undergo mechanical stimulation over 20 minutes once daily (QD) beginning on date of hospital admission and continuing through day 100 post-HCT, except for day 0 (date of transplant).
Study Design
Arms and Interventions
Arm | Intervention/Treatment |
---|---|
Experimental: Supportive care (whole body vibration) Patients undergo mechanical stimulation over 20 minutes QD beginning on date of hospital admission and continuing through day 100 post-HCT, except for day 0 (date of transplant). |
Procedure: management of therapy complications
Undergo mechanical stimulation
Other Names:
Procedure: musculoskeletal complications management/prevention
Undergo mechanical stimulation
Other Names:
|
Outcome Measures
Primary Outcome Measures
- Refinement of mechanical stimulation protocol [From hospital admission to 100 days post-HCT]
Best time of day for treatment, staff involvement, etc.
- Adherence with treatment [From hospital admission to 100 days post-HCT]
- Effective data collection tools and data points [From hospital admission to 100 days post-HCT]
Eligibility Criteria
Criteria
Inclusion Criteria:
-
Meet eligibility criteria for first allogeneic HCT, and are scheduled to undergo allogeneic HCT
-
Pre-transplant Karnofsky Performance Status (KPS) >= 70
-
Patient or legal representative must understand the investigational nature of this study and sign an Institutional Review Board approved written informed consent form prior to receiving any study related procedure
Exclusion Criteria:
-
Any prior allogeneic HCT
-
Pre-transplant weight >= 280 lbs
-
Body mass index (BMI) < l8kg/m^2
-
Human leukocyte antigen (HLA)-mismatched HCT
-
Cord blood transplant
-
Osteopenia or osteoporosis (T-score =< -1.0)
-
Multiple myeloma diagnosis
-
Any prior history of a central nervous system (CNS) hemorrhage
-
Currently treated with a therapeutic dose of anti-coagulation for a recent pulmonary embolism or deep vein thrombosis
-
Current or previous bisphosphonate use
-
Prior history of non-traumatic fracture
-
Any screws, pins, rods, or other metal objects in the body
-
Total joint replacement
-
History of kidney stones or gall stones
-
Any artificial limbs
-
Pregnant or nursing female patients
-
Unwilling or unable to follow protocol requirements
-
Any condition which in the Investigator's opinion deems the patient an unsuitable candidate to receive study intervention
Contacts and Locations
Locations
No locations specified.Sponsors and Collaborators
- Roswell Park Cancer Institute
Investigators
- Principal Investigator: Philip McCarthy, Roswell Park Cancer Institute
Study Documents (Full-Text)
None provided.More Information
Publications
None provided.- I 190510
- NCI-2011-02354